Upadacitinib Monotherapy Shows Positive Results in Rheumatoid Arthritis Trial

AbbVie announces positive top-line results from the SELECT-EARLY phase 3 study showing that both 15 mg and 30 mg doses of upadacitinib monotherapy met the primary endpoints of ACR50 at week 12, and clinical remission at week 24 versus methotrexate in adult patients with moderate to severe rheumatoid arthritis, methotrexate-naïve.

Additionally, all secondary endpoints were also achieved.

“SELECT-EARLY is the fifth pivotal trial that will support regulatory submissions for upadacitinib in rheumatoid arthritis later this year,” Michael Severino, MD, executive vice president, research and development, chief scientific officer, AbbVie, said in a statement. “Results from the SELECT-EARLY further support our belief that upadacitinib has the potential to be an important new treatment option for patients with rheumatoid arthritis.”

In the first phase of the SELECT-EARLY phase 3 study, patients were randomized 1:1:1 to receive upadacitinib 15 mg or 30 mg daily, or methotrexate. Additionally, it includes a Japan sub-study in which subjects were randomized 2:1:1:1 to receive upadacitinib 7.5 mg, 15 mg, 30 mg daily or methotrexate.

Primary endpoints included the percentage of patients achieving ACR50 after 12 weeks of treatment, and clinical remission after 24 weeks of treatment versus methotrexate, while secondary endpoints included the proportion of patients achieving ACR20, ACR70 and low disease activity in addition to changes in the modified total Sharp score in the Health Assessment Questionnaire-Disability-Index (HAQ-DI). Both endpoints were met.
 
Click to continue reading on MD Magazine.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Top news of the day from across the health care landscape.
Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$